By Fineline Cube 
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced today that its programmed death‑1 (PD‑1) antibody LOQTORZI (toripalimab) has received Health Canada approval. The approval constitutes the first and only Canadian‑licensed immunotherapy for patients with recurrent unresectable or metastatic nasopharyngeal carcinoma (R/M NPC).
Product Profile
- Mechanism – LOQTORZI blocks PD‑1 signaling, restoring T‑cell activity against tumor cells.
- Global Track Record – Over 40 company‑sponsored trials span more than 15 indications across China, the United States, Europe, and Southeast Asia. In mainland China, the drug has gained approval for 12 distinct indications.
Canadian Indications
- Combination Therapy – In adults with metastatic or recurrent locally advanced NPC, LOQTORZI is indicated in combination with cisplatin and gemcitabine.
- Monotherapy – For adults with R/M NPC who have progressed after platinum‑based chemotherapy, LOQTORZI can be administered as a single agent.
Strategic Significance
- Market Expansion – The Canadian approval opens a new North‑American market for Junshi’s portfolio, complementing its strong presence in Asia.
- Patient Impact – This is the first immunotherapy specifically approved in Canada for R/M NPC, addressing an unmet therapeutic need.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech